Familial Hypophosphatemia and Related Disorders

Pediatric Bone

Volumn , Issue , 2012, Pages 699-726

  Holm, Ingrid A ^a   Econs, Michael J ^b   Carpenter, Thomas O ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882810295     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-382040-2.10026-7     Document Type: Chapter

References (260)

1. Tenenhouse H.S., Econs M.J. Mendelian hypophosphatemias. The Metabolic and Molecular Basis of Inherited Disease 2001, 5039-5068. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Tenenhouse H.S. Phosphate transport: molecular basis, regulation and pathophysiology. J Steroid Biochem Mol Biol 2007, 103:572-577.
3. Bastepe M., Jüppner H. Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord 2008, 9:171-180.
4. Prié D., Friedlander G. Genetic disorders of renal phosphate transport. N Engl J Med 2010, 362:2399-2409.
5. Gisler S.M., Stagljar I., Traebert M., Bacic D., Biber J., Murer H. Interaction of the type IIa Na/Pi cotransporter with PDZ proteins. J Biol Chem 2001, 276:9206-9213.
6. Hernando N., Deliot N., Gisler S.M., et al. PDZ domain interactions and apical expression of type IIa Na/P(i) cotransporters. Proc Natl Acad Sci USA 2002, 99:11957-11962.
7. Rasmussen H., Tenenhouse H.S. Mendelian hypophosphatemias. The Metabolic and Molecular Basis of Inherited Disease 1995, 3717-3745. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
8. Tenenhouse H.S. Cellular and molecular mechanisms of renal phosphate transport. J Bone Miner Res 1997, 12:159-164.
9. Reid I.R., Hardy D.C., Murphy W.A., Teitelbaum S.L., Bergfeld M.A., Whyte M.P. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine 1989, 68:336-352.
10. Burnett C.H., Dent C.E., Harper C., Warland B.J. Vitamin D-resistant rickets. Am J Med 1964, 36:222-232.
11. Econs M.J., Feussner J.R., Samsa G.P., et al. X-linked hypophosphatemic rickets without "rickets". Skeletal Radiol 1991, 20:109-114.
12. Block J.E., Piel C.F., Selvidge R., Genant H.K. Familial hypophosphatemic rickets: bone mass measurements in children following therapy with calcitriol and supplemental phosphate. Calcif Tissue Int 1989, 44:86-92.
13. Reid I.R., Murphy W.A., Hardy D.C., Teitelbaum S.L., Bergfeld M.A., Whyte M.P. X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry. Am J Med 1991, 90:63-69.
14. Oliveri M.B., Cassinelli H., Bergada C., Mautalen C.A. Bone mineral density of the spine and radius shaft in children with X-linked hypophosphatemic rickets (XLH). Bone Miner 1991, 12:91-100.
15. Rosenthall L. DEXA bone densitometry measurements in adults with X-linked hypophosphatemia. Clin Nucl Med 1993, 18:564-566.
16. Shore R.M., Langman C.B., Poznanski A.K. Lumbar and radial bone mineral density in children and adolescents with X-linked hypophosphatemia: evaluation with dual X-ray absorptiometry. Skeletal Radiol 2000, 29:90-93.
17. Berndt M., Ehrich J.H., Lazovic D., et al. Clinical course of hypophosphatemic rickets in 23 adults. Clin Nephrol 1996, 45:33-41.
18. Ferris B., Walker C., Jackson A., Kirwan E. The orthopaedic management of hypophosphataemic rickets. J Pediatr Orthop 1991, 11:367-373.
19. Chalmers J. Enthesopathy as the presenting feature of X-linked hypophosphatemia. A case report. Acta Orthop Scand 1993, 64:221-223.
20. Marie P.J., Glorieux F.H. Bone histomorphometry in asymptomatic adults with hereditary hypophosphatemic vitamin D-resistant osteomalacia. Metab Bone Dis Relat Res 1982, 4:249-253.
21. Marie P.J., Glorieux F.H. Histomorphometric study of bone remodeling in hypophosphatemic vitamin D-resistant rickets. Metab Bone Dis Relat Res 1981, 3:31-38.
22. Rowe P.S., Matsumoto N., Jo O.D., et al. Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone 2006, 39:773-786.
23. Sullivan W., Carpenter T., Glorieux F., Travers R., Insogna K. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 1992, 75:879-885.
24. Verge C.F., Cowell C.T., Howard N.J., Donaghue K.C., Silink M. Growth in children with X-linked hypophosphataemic rickets. Acta Paediatr Suppl 1993, 388:70-76.
25. Steendijk R., Herweijer T.J. Height, sitting height and leg length in patients with hypophosphataemic rickets. Acta Paediatr Scand 1984, 73:181-184.
26. Steendijk R., Hauspie R.C. The pattern of growth and growth retardation of patients with hypophosphataemic vitamin D-resistant rickets: a longitudinal study. Eur J Pediatr 1992, 151:422-427.
27. Balsan S., Tieder M. Linear growth in patients with hypophosphatemic vitamin D-resistant rickets: influence of treatment regimen and parental height [see Comments]. J Pediatr 1990, 116:365-371.
28. Friedman N.E., Lobaugh B., Drezner M.K. Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 1993, 76:839-844.
29. McWhorter A.G., Seale N.S. Prevalence of dental abscess in a population of children with vitamin D-resistant rickets. Pediatr Dent 1991, 13:91-96.
30. Abe K., Ooshima T., Lily T.S., Yasufuku Y., Sobue S. Structural deformities of deciduous teeth in patients with hypophosphatemic vitamin D-resistant rickets. Oral Surg Oral Med Oral Pathol 1988, 65:191-198.
31. Hillmann G., Geurtsen W. Pathohistology of undecalcified primary teeth in vitamin D-resistant rickets: Review and report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996, 82:18-24.
32. Seeto E., Seow W.K. Scanning electron microscopic analysis of dentin in vitamin D-resistant rickets - assessment of mineralization and correlation with clinical findings. Pediatr Dent 1991, 13:43-48.
33. Goodman J.R., Gelbier M.J., Bennett J.H., Winter G.B. Dental problems associated with hypophosphataemic vitamin D resistant rickets. Int J Paediatr Dent 1998, 8:19-28.
34. Seow W.K., Needleman H.L., Holm I.A. Effect of familial hypophosphatemic rickets on dental development: a controlled, longitudinal study. Pediatr Dent 1995, 17:346-350.
35. Larmas M., Hietala E.L., Simila S., Pajari U. Oral manifestations of familial hypophosphatemic rickets after phosphate supplement therapy: A review of the literature and report of case. J Dent Child 1991, 58:328-334.
36. Seow W.K. The effect of medical therapy on dentin formation in vitamin D-resistant rickets. Pediatr Dent 1991, 13:97-102.
37. Velan G.J., Currier B.L., Clarke B.L., Yaszemski M.J. Ossification of the posterior longitudinal ligament in vitamin D-resistant rickets: case report and review of the literature. Spine 2001, 26:590-593.
38. Matsui H., Katoh Y., Tsuji H. Untreated hypophosphatemic vitamin D-resistant rickets with symptomatic ossification of the ligamenturn flavum. J Spinal Disord 1991, 4:110-113.
39. Dunlop D.J., Stirling A.J. Thoracic spinal cord compression caused by hypophosphataemic rickets: a case report and review of the world literature. Eur Spine J 1996, 5:272-274.
40. Bradbury P.G., Brenton D.P., Stern G.M. Neurological involvement in X-linked hypophosphataemic rickets. J Nenrol Neurosurg Psychiatr 1987, 50:810-812.
41. Ballantyne E.S., Findlay G.F. Thoracic spinal stenosis in two brothers due to vitamin D-resistant rickets. Eur Spine J 1996, 5:125-127.
42. Yamamoto Y., Onofrio B.M. Spinal canal stenosis with hypophosphatemic vitamin D-resistant rickets: case report. Neurosurgery 1994, 35:512-515.
43. Caldemeyer K.S., Boaz J.C., Wappner R.S., Moran C.C., Smith R.R., Quets J.P. Chiari I malformation: association with hypophosphatemic rickets and MR imaging appearance. Radiology 1995, 195:733-738.
44. O'Malley S.P., Adams J.E., Davies M., Ramsden R.T. The petrous temporal bone and deafness in X-linked hypophosphataemic osteomalacia. Clin Radiol 1988, 39:528-530.
45. Boneh A., Reade T.M., Scriver C.R., Rishikof E. Audiometric evidence for two forms of X-linked hypophosphatemia in humans, apparent counterparts of Hyp and Gy mutations in mouse. Am J Med Genet 1987, 27:997-1003.
46. Meister M., Johnson A., Popelka G.R., Kim G.S., Whyte M.P. Audiologic findings in young patients with hypophosphatemic bone disease. Ann Otol Rhinol Laryngol 1986, 95:415-420.
47. O'Malley S., Ramsden R.T., Latif A., Kane R., Davies M. Electrocochleographic changes in the hearing loss associated with X-linked hypophosphataemic osteomalacia. Acta Otolaryngol 1985, 100:13-18.
48. Nehgme R., Fahey J.T., Smith C., Carpenter T.O. Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 1997, 82:2450-2454.
49. Carpenter T.O., Mitnick M.A., Ellison A., Smith C., Insogna K.L. Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab 1994, 78:1378-1383.
50. Carpenter T.O., Key L.L. Disorders of the metabolism of calcium, phosphorus, and other minerals. Pediatric Textbook of Fluids and Electrolytes 1990, 237-268. Williams & Wilkins, Baltimore. I. Ichikawa (Ed.).
51. Carpenter T.O. New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr Clin North Am 1997, 44:43-66.
52. Bijvoet O.L.M. Kidney function in calcium and phosphate metabolism. Metabolic Bone Disease 1977, 49-69. Academic Press, New York. L.V. Avioli, S.M. Krane (Eds.).
53. Walton R.J., Bijvoet O.L. A simple slide-rule method for the assessment of renal tubular reaborption of phosphate in man. Clin Chim Acta 1977, 81:273-276.
54. Walton R.J., Bijvoet O.L. Nomogram for derivation of renal threshold phosphate concentration. Lancet 1975, 2:309-310.
55. Chesney R.W. Fanconi syndrome and renal tubular acidosis. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 1999, 340-343. Lippincott-Raven, Philadelphia. M.J. Favus (Ed.).
56. Francis F., Rowe P.S., Econs M.J., et al. A YAC contig spanning the hypophosphatemic rickets disease gene (HYP) candidate region. Genomics 1994, 21:229-237.
57. Rowe P.S., Goulding J., Read A., et al. Refining the genetic map for the region flanking the X-linked hypophosphataemic rickets locus (Xp22.1-22.2). Hum Genet 1994, 93:291-294.
58. Thakker R.V., Farmery M.R., Sakati N.A., Milner R.D. Genetic linkage studies of X-linked hypophosphataemic rickets in a Saudi Arabian family. Clin Endocrinol 1992, 37:338-343.
59. Alitalo T., Kruse T.A., Ahrens P., Albertsen H.M., Eriksson A.W., Chapelle A.D.L. Genetic mapping of 12 marker loci in the Xp22.3-p21.2 region. Hum Genet 1991, 86:599-603.
60. Thakker R.V., Davies K.E., Read A.P., et al. Linkage analysis of two cloned DNA sequences, DXS197 and DXS207, in hypophosphatemic rickets families. Genomics 1990, 8:189-193.
61. Thakker R.V., Read A.P., Davies K.E., et al. Bridging markers defining the map position of X linked hypophosphataemic rickets. J Med Genet 1987, 24:756-760.
62. Machler M., Frey D., Gal A., et al. X-linked dominant hypophosphatemia is closely linked to DNA markers DXS41 and DXS43 at Xp22. Hum Genet 1986, 73:271-275.
63. Read A.P., Thakker R.V., Davies K.E., et al. Mapping of human X-linked hypophosphataemic rickets by multilocus linkage analysis. Hum Genet 1986, 73:267-270.
64. Econs M.J., Barker D.F., Speer M.C., Pericak-Vance M.A., Fain P., Drezner M.K. Multilocus mapping of the human X-linked hypophosphatemic rickets gene locus. J Bone Miner Res 1990, 5. S108.
65. Econs M.J., Barker D.F., Speer M.C., Pericak-Vance M.A., Fain P.R., Drezner M.K. Multilocus mapping of the X-linked hypophosphatemic rickets gene. J Clin Endocrinol Metab 1992, 75:201-206.
66. Econs M.J., Fain P.R., Norman M., et al. Flanking markers define the X-linked hypophosphatemic rickets gene locus. J Bone Miner Res 1993, 8:1149-1152.
67. Econs M.J., Rowe P.S., Francis F., et al. Fine structure mapping of the human X-linked hypophosphatemic rickets gene locus. J Clin Endocrinol Metab 1994, 79:1351-1354.
68. Consortium H.Y.P. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nature Genet 1995, 11:130-136.
69. D'Adamio L., Shipp M.A., Masteller E.L., Reinherz E.L. Organization of the gene encoding common acute lymphoblast miniexons and separate 5' untranslated regions. Proc Natl Acad Sci USA 1989, 86:7103-7107.
70. Xu D., Emoto N., Giaid A., et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994, 78:473-485.
71. Lee S., Zambas E.D., Marsh W.L., Redman C.M. Molecular cloning and primary structure of Kell blood group protein. Proc Natl Acad Sci USA 1991, 88:6353-6357.
72. Beck L., Soumounou Y., Martel J., et al. Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 1997, 99:1200-1209.
73. Grieff M., Mumm S., Waeltz P., et al. Expression and cloning of the human X-linked hypophosphatemia gene cDNA. Biochem Biophys Res Commun 1997, 231:635-639.
74. Francis F., Strom T.M., Hennig S., et al. Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets. Genome Res 1997, 7:573-585.
75. Holm I.A., Huang X., Kunkel L.M. Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet 1997, 60:790-797.
76. Holm I.A., Nelson A.E., Robinson B.G., et al. Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2001, 86:3889-3899.
77. Dixon P.H., Wooding C., Trump D., Schlessinger D., Whyte M.P., Thakker R.V. Seven novel mutations in the PEX gene indicate molecular heterogeneity for X-linked hypophosphatemic rickets. J Bone Miner Res 1996, 11. S136.
78. Dixon P.H., Wooding C., Christie P., et al. Twelve novel PEX mutations in X-linked hypophosphatemic rickets indicate molecular heterogeneity. [Abstract OC12]. J Endocrinol 1997, 152.
79. Dixon P.H., Christie P.T., Wooding C., et al. Mutational analysis of PHEX gene in X-linked hypophosphatemia. J Clin Endocrinol Metab 1998, 83:3615-3623.
80. Rowe P.S., Oudet C.L., Francis F., et al. Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet 1997, 6:539-549.
81. Tyynismaa H., Kaitila I., Nanto-Salonen K., Ala-Houhala M., Alitalo T. Identification of fifteen novel PHEX gene mutations in Finnish patients with hypophosphatemic rickets. Hum Mutat 2000, 15:383-384.
82. Filisetti D., Ostermann G., Von Bredow M., et al. Non-random distribution of mutations in the PHEX gene, and under-detected missense mutations at non-conserved residues. Eur J Hum Genet 1999, 7:615-619.
83. Sato K., Tajima T., Nakae J., et al. Three novel PHEX gene mutations in Japanese patients with X-linked hypophosphatemic rickets. Pediatr Res 2000, 48:536-540.
84. Christie P.T., Harding B., Nesbit M.A., Whyte M.P., Thakker R.V. X-linked hypophosphatemia attributable to pseudoexons of the PHEX gene. J Clin Endocrinol Metab 2001, 86:3840-3844.
85. Consortium A.D.H.R. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF-23. Nature Genet 2000, 26:345-348.
86. Sabbagh Y., Jones A.O., Tenenhouse H.S. PHEXdb, a locus-specific database for mutations causing X-linked hypophosphatemia. Hum Mutat 2000, 16:1-6.
87. Winters R.W., Graham J.B., Williams T.F., McFalls V.W., Burnett C.H. A genetic study of familial hypophosphatemia and vitamin D-resistant rickets with a review of the literature. Medicine 1958, 37:97.
88. Whyte M.P., Schranck F.W., Armamento-Villareal R. X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab 1996, 81:4075-4080.
89. Shields E.D., Scriver C.R., Reade T., et al. X-linked hypophosphatemia: the mutant gene is expressed in teeth as well as in kidney. Am J Hum Genet 1990, 46:434-442.
90. Scriver C.R., Tenenhouse H.S. X-linked hypophosphataemia: a homologous phenotype in humans and mice with unusual organ-specific gene dosage. J Inherit Metab Dis 1992, 15:610-624.
91. Petersen D.J., Boniface A.M., Schranck F.W., Rupich R.C., Whyte M.P. X-linked hypophosphatemic rickets: a study (with literature review) of linear growth response to calcitriol and phosphate therapy. J Bone Miner Res 1992, 7:583-597.
92. Hardy D.C., Murphy W.A., Siegel B.A., Reid I.R., Whyte M.P. X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. Radiology 1989, 171:403-414.
93. Orstavi K.H., Orstavik R.E., Halse J., Knudtzon J. X chromosome inactivation pattern in female carriers of X linked hypophosphataemic rickets. J Med Genet 1996, 33:700-703.
94. Gattineni J., Baum M. Regulation of phosphate transport by fibroblast growth factor 23 (FGF-23): implications for disorders of phosphate metabolism. Pediatr Nephrol 2010, 25:591-601.
95. Ramon I., Kleynen P., Body J.J., Karmali R. Fibroblast growth factor 23 and its role in phosphate homeostasis. Eur J Endocrinol 2010, 162:1-10.
96. Strom T.M., Jüppner H. PHEX, FGF-23, DMP1 and beyond. Curr Opin Nephrol Hypertens 2008, 17:357-362.
97. Seikaly M.G., Brown R., Baum M. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics 1997, 100:879-884.
98. Haffner D., Wuhl E., Blum W.F., Schaefer F., Mehls O. Disproportionate growth following long-term growth hormone treatment in short children with X-linked hypophosphataemia. Eur J Pediatr 1995, 154:610-613.
99. Patel L., Clayton P.E., Brain C., et al. Acute biochemical effects of growth hormone treatment compared with conventional treatment in familial hypophosphataemic rickets. Clin Endocrinol 1996, 44:687-696.
100. Alon U.S., Levy-Olomucki R., Moore W.V., Stubbs J., Liu S., Quarles L.D. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 2008, 3:658-664.
101. Alon U., Chan J.C. Effects of hydrochlorothiazide and amiloride in renal hypophosphatemic rickets. Pediatrics 1985, 75:754-763.
102. Dietz F.R. A primer of osteotomy of the weight bearing long bones in children. Iowa Orthop J 1993, 13:136-148.
103. Rubinovitch M., Said S.E., Glorieux F.H., Cruess R.L., Rogala E. Principles and results of corrective lower limb osteotomies for patients with vitamin D-resistant hypophosphatemic rickets. Clin Orthop Rel Res 1988, 237:264-270.
104. Kanel J.S., Price C.T. Unilateral external fixation for corrective osteotomies in patients with hypophosphatemic rickets. J Pediatr Orthop 1995, 15:232-235.
105. Novais E., Stevens P.M. Hypophosphatemic rickets: the role of hemiepiphysiodesis. J Pediatr Orthop 2006, 26:238-244.
106. Bettinelli A., Bianchi M.L., Mazzucchi E., Gandolini G., Appiani A.C. Acute effects of calcitriol and phosphate salts on mineral metabolism in children with hypophosphatemic rickets. J Pediatr 1991, 118:372-376.
107. Yamaoka K., Tanaka H., Kurose H., et al. Effect of single oral phosphate loading on vitamin D metabolites in normal subjects and in X-linked hypophosphatemic rickets. Bone Miner 1989, 7:159-169.
108. Verge C.F., Lam A., Simpson J.M., Cowell C.T., Howard N.J., Silink M. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 1991, 325:1843-1848.
109. Kooh S.W., Binet A., Daneman A. Nephrocalcinosis in X-linked hypophosphataemic rickets: its relationship to treatment, kidney function, and growth. Clin Invest Med 1994, 17:123-130.
110. Reusz G.S., Latta K., Hoyer P.F., Byrd D.J., Ehrich J.H., Brodehl J. Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated hypophosphataemic rickets. Lancet 1990, 335:1240-1243.
111. Alon U., Donaldson D.L., Hellerstein S., Warady B.A., Harris D.J. Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the Hyp mouse. J Pediatr 1992, 120:899-905.
112. Polisson R.P., Martinez S., Khoury M., et al. Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med 1985, 313:1-6.
113. Caldemeyer K.S., Smith R.R., Edwards-Brown M.K. Familial hypophosphatemic rickets causing ocular calcification and optic canal narrowing. Am J Neuroradiol 1995, 16:1252-1254.
114. Moltz K.C., Friedman A.H., Nehgme R.A., Kleinman C.S., Carpenter T.O. Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets. Curr Opin Pediatr 2001, 13:373-375.
115. Bianchine J.W., Stambler A.A., Harrison H.E. Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser 1971, 7:287-294.
116. Econs M.J., McEnery P.T. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997, 82:674-681.
117. Imel E., Gray A., Econs M. FGF-23 is related to serum iron concentrations in ADHR. J Bone Miner Res 2009, 24(S1). Available at, Accessed February 10, 2011. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=d5dc ac8e-264e-47d3-9291-b37ecb57c8e6.
118. Imel E.A., Hui S.L., Econs M.J. FGF-23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 2007, 22:520-526.
119. Feng J.Q., Ward L.M., Liu S., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006, 38:1310-1315.
120. Lorenz-Depiereux B., Bastepe M., Benet-Pagès A., et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006, 38:1248-1250.
121. Zhang B., Sun Y., Chen L., Guan C., Guo L., Qin C. Expression and distribution of SIBLING proteins in the predentin/dentin and mandible of hyp mice. Oral Dis 2010, 16:453-464.
122. Harmey D., Hessle L., Narisawa S., Johnson K.A., Terkeltaub R., Millán J.L. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004, 164:1199-1209.
123. Lorenz-Depiereux B., Schnabel D., Tiosano D., Häusler G., Strom T.M. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010, 86:267-272.
124. Levy-Litan V., Hershkovitz E., Avizov L., et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 2010, 86:273-278.
125. Rutsch F., Ruf N., Vaingankar S., et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003, 34:379-381.
126. Rutsch F., Böyer P., Nitschke Y., et al. GACI Study Group. Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet 2008, 1:133-140.
127. Tieder M., Modai D., Samuel R., et al. Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 1985, 312:611-617.
128. Chen C., Carpenter T., Steg N., Baron R., Anast C. Hypercalciuric hypophosphatemic rickets, mineral balance, bone histomorphometry, and therapeutic implications of hypercalciuria. Pediatrics 1989, 84:276-280.
129. Tieder M., Modai D., Shaked U., et al. "Idiopathic" hypercalciuria and hereditary hypophosphatemic rickets. Two phenotypical expressions of a common genetic defect. N Engl J Med 1987, 316:125-129.
130. Pak C.Y.C. Kidney stones. Williams Textbook of Endocrinology 1998, 1241-1257. Saunders, Philadelphia. J.D. Wilson, D.W. Foster, H.M. Kronenberg, P.R. Larsen (Eds.).
131. Jones A., Tzenova J., Frappier D., et al. Hereditary hypophosphatemic rickets with hypercalciuria is not caused by mutations in the Na/Pi cotransporter NPT2 gene. J Am Soc Nephrol 2001, 12:507-514.
132. Van den Heuvel L., Op de Koul K., Knots E., Knoers N., Monnens L. Autosomal recessive hypophosphataemic rickets with hypercalciuria is not caused by mutations in the type II renal sodium/phosphate cotransporter gene. Nephrol Dial Transplant 2001, 16:48-51.
133. Jaureguiberry G., Carpenter T.O., Forman S., Jüppner H., Bergwitz C. A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. Am J Physiol Renal Physiol 2008, 295:F371-F379.
134. Magen D., Berger L., Coady M.J., et al. A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome. N Engl J Med 2010, 362:1102-1109.
135. Klein G.L., Dallas J.S., Hawkins H.K., Swischuk L.E., McCauley R.L. Congenital linear sebaceous nevus syndrome. J Bone Miner Res 1998, 13:1056-1057.
136. Drezner M.K. Tumor-induced rickets and osteomalacia. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 1999, 331-337. Lippincott-Raven, Philadelphia. M.J. Favus (Ed.).
137. Agus Z.S. Oncogenic hypophosphatemic osteomalacia. Kidney Int 1983, 24:113-123.
138. Eyskens B., Proesmans W., Van Damme B., Lateur L., Bouillon R., Hoogmartens M. Tumour-induced rickets: a case report and review of the literature. Eur J Pediatr 1995, 154:462-468.
139. Schapira D., Ben Izhak O., Nachtigal A., et al. Tumor-induced osteomalacia. Sem Arthritis Rheum 1995, 25:35-46.
140. Cheng C.L., Ma J., Wu P.C., Mason R.S., Posen S. Osteomalacia secondary to osteosarcoma. A case report. J Bone Joint Surg Am 1989, 71:288-292.
141. Weidner N., Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 1987, 59:1442-1454.
142. Folpe A.L., Fanburg-Smith J.C., Billings S.D., et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004, 28:1-30.
143. Nguyen B.D., Wang E.A. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med 1999, 24:130-131.
144. Ohashi K., Ohnishi T., Ishikawa T., Tani H., Uesugi K., Takagi M. Oncogenic osteomalacia presenting as bilateral stress fractures of the tibia. Skeletal Radiol 1999, 28:46-48.
145. Reyes-Mugica M., Arnsmeier S.L., Backeljauw P.F., Persing J., Ellis B., Carpenter T.O. Phosphaturic mesenchymal tumor-induced rickets. Pediatr Dev Pathol 2000, 3:61-69.
146. Shane E., Parisien M., Henderson J.E., et al. Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res 1997, 12:1502-1511.
147. Yeung S.J., McCutcheon I.E., Schultz P., Gagel R.F. Use of long-term intravenous phosphate infusion in the palliative treatment of tumor-induced osteomalacia. J Clin Endocrinol Metab 2000, 85:549-555.
148. Seufert J., Ebert K., Muller J., et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 2001, 345:1883-1888.
149. Aschinberg L.C., Solomon L.M., Zeis P.M., Justice P., Rosenthal I.M. Vitamin D-resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in the dermal lesions. J Pediatr 1977, 91:56-60.
150. White K.E., Jonsson K.B., Cam G., et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001, 86:497-500.
151. Bowe A.E., Finnegan R., Jan de Beur S.M., et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001, 284:977-981.
152. Shimada T., Mizutani S., Muto T., et al. Cloning and characterization of FGF-23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001, 98:6500-6505.
153. Shimada T., Urakawa I., Yamazaki Y., et al. FGF-23 Transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Common 2004, 314:409-414.
154. Kumar R. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr Opin Nephrol Hypertens 2002, 11:547-553.
155. Schiavi S.C., Moe O.W. Phosphatonins: a new class of phosphate-regulating proteins. Curr Opin Nephrol Hypertens 2002, 11:423-430.
156. Vassiliadis J., Jan de Beur S.M., Bowe A.E., et al. Frizzled related protein 4 expression is elevated in tumors associated with oncogenic osteomalacia and inhibits phosphate transport in vitro. J Bone Miner Res 2001, 16. S225.
157. Olivares J.L., Ramos F.J., Carapeto F.J., Bueno M. Epidermal naevus syndrome and hypophosphataemic rickets: description of a patient with central nervous system anomalies and review of the literature. Eur J Pediatr 1999, 158:103-107.
158. Heike C.L., Cunningham M.L., Steiner R.D., et al. Skeletal changes in epidermal nevus syndrome: does focal bone disease harbor clues concerning pathogenesis?. Am J Med Genet A 2005, 139A:67-77.
159. Hoffman W.H., Jueppner H.W., Deyoung B.R., O'dorisio M.S., Given K.S. Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am J Med Genet 2005, 134:233-236.
160. Sethi S.K., Hari P., Bagga A. Elevated FGF-23 and parathormone in linear nevus sebaceous syndrome with resistant rickets. Pediatr Nephrol 2010, 25:1577-1578.
161. Hafner C., van Oers J.M., Vogt T., et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 2006, 116:2201-2207.
162. Collins M.T., Chebli C., Jones J., et al. Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 2001, 16:806-813.
163. Dent C.E., Gertner J.M. Hypophosphataemic osteomalacia in fibrous dysplasia. Q J Med 1976, 45:411-420.
164. Riminucci M., Collins M.T., Fedarko N.S., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003, 112:683-692.
165. John M.R., Wickert H., Zaar K., et al. A case of neuroendocrine oncogenic osteomalacia associated with a PHEX and fibroblast growth factor-23 expressing sinusoidal malignant schwannoma. Bone 2001, 29:393-402.
166. Konishi K., Nakamura M., Yamakawa H., et al. Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis. Am J Med Sci 1991, 301:322-328.
167. Eicher E.M., Southard J.L., Scriver C.R., Glorieux F.H. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci USA 1976, 73:4667-4671.
168. Lyon M.F., Scriver C.R., Baker L.R., Tenenhouse H.S., Kronick J., Mandla S. The Gy mutation: another cause of X-linked hypophosphatemia in mouse. Proc Natl Acad Sci USA 1986, 83:4899-4903.
169. O'Doherty P.J., DeLuca H.F., Eicher E.M. Lack of effect of vitamin D and its metabolites on intestinal phosphate transport in familial hypophosphatemia of mice. Endocrinology 1977, 101:1325-1330.
170. Tenenhouse H.S., Scriver C.R. The defect in transcellular transport of phosphate in the nephron is located in brush-border membranes in X-linked hypophosphatemia (Hyp mouse model). Can J Biochem 1978, 56:640-646.
171. Tenenhouse H.S., Scriver C.R., McInnes R.R., Glorieux F.H. Renal handling of phosphate in vivo and in vitro by the X-linked hypophosphatemic male mouse: evidence for a defect in the brush border membrane. Kidney Int 1978, 14:236-244.
172. Tenenhouse H.S., Scriver C.R., Vizel E.J. Alkaline phosphatase activity does not mediate phosphate transport in the renal-cortical brush-border membrane. Biochem J 1980, 190:473-476.
173. Tenenhouse H.S., Klugerman A.H., Neal J.L. Effect of phosphonoformic acid, dietary phosphate and the Hyp mutation on kinetically distinct phosphate transport processes in mouse kidney. Biochim Biophys Acta 1989, 984:207-213.
174. Perwad F., Azam N., Zhang M.Y., Yamashita T., Tenenhouse H.S., Portale A.A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005, 146:5358-5364.
175. Kiebzak G.M., Roos B.A., Meyer R.A. Secondary hyperparathyroidism in X-linked hypophosphatemic mice. Endocrinology 1982, 111:650-652.
176. Posillico J.T., Lobaugh B., Muhlbaier L.H., Drezner M.K. Abnormal parathyroid function in the X-linked hypophosphatemic mouse. Calcif Tissue Int 1985, 37:418-422.
177. Meyer R.A., Meyer M.H., Morgan P.L. Effects of altered diet on serum levels of 1,25-dihydroxyvitamin D and parathyroid hormone in X-linked hypophosphatemic (Hyp and Gy) mice. Bone 1996, 18:23-28.
178. Ecarot-Charrier B., Glorieux F.H., Travers R., Desbarats M., Bouchard F., Hinek A. Defective bone formation by transplanted Hyp mouse bone cells into normal mice. Endocrinology 1988, 123:768-773.
179. Marie P.J., Travers R., Glorieux F.H. Healing of rickets with phosphate supplementation in the hypophosphatemic male mouse. J Clin Invest 1981, 67:911-914.
180. Marie P.J., Travers R., Glorieux F.H. Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse. Calcif Tissue Int 1982, 34:158-164.
181. Ecarot B., Glorieux F.H., Desbarats M., Travers R., Labelle L. Defective bone formation by Hyp mouse bone cells transplanted into normal mice: evidence in favor of an intrinsic osteoblast defect. J Bone Miner Res 1992, 7:215-220.
182. Ecarot B., Glorieux F.H., Desbarats M., Travers R., Labelle L. Effect of 1,25-dihydroxyvitamin D3 treatment on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice. J Bone Miner Res 1995, 10:424-431.
183. Ecarot B., Glorieux F.H., Desbarats M., Travers R., Labelle L. Effect of dietary phosphate deprivation and supplementation of recipient mice on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice. J Bone Miner Res 1992, 7:523-530.
184. Iorio R.J., Bell W.A., Meyer M.H., Meyer R.A. Radiographic evidence of craniofacial and dental abnormalities in the X-linked hypophosphatemic mouse. Ann Dent 1979, 38:31-37.
185. Iorio R.J., Bell W.A., Meyer M.H., Meyer R.A. Histologic evidence of calcification abnormalities in teeth and alveolar bone of mice with X-linked dominant hypophosphatemia (VDRR). Ann Dent 1979, 38:38-44.
186. Sofaer J.A., Southam J.C. Naturally-occurring exposure of the dental pulp in mice with inherited hypophosphataemia. Arch Oral Biol 1982, 27:701-703.
187. Abe K., Ooshima T., Masatomi Y., Sobue S., Moriwaki Y. Microscopic and crystallographic examinations of the teeth of the X-linked hypophosphatemic mouse. J Dent Res 1989, 68:1519-1524.
188. Abe K., Masatomi Y., Nakajima Y. The occurrence of interglobular dentin in incisors of hypophosphatemic mice fed a high-calcium and high-phosphate diet. J Dental Res 1992, 71:478-483.
189. Yamaoka K., Seino Y., Satomura K., Tanaka Y., Yabuuchi H., Haussier M.R. Abnormal relationship between serum phosphate concentration and renal 25-hydroxycholecalciferol-1-alpha-hydroxylase activity in X-linked hypophosphatemic mice. Miner Electrolyte Metab 1986, 12:194-198.
190. Tenenhouse H.S., Jones G. Abnormal regulation of renal vitamin D catabolism by dietary phosphate in murine X-linked hypophosphatemic rickets. J Clin Invest 1990, 85:1450-1455.
191. Roy S., Martel J., Ma S., Tenenhouse H.S. Increased renal 25-hydroxyvitamin D3-24-hydroxylase messenger ribonucleic acid and immunoreactive protein in phosphate-deprived Hyp mice: a mechanism for accelerated 1,25-dihydroxyvitamin D3 catabolism in X-linked hypophosphatemic rickets. Endocrinology 1994, 134:1761-1767.
192. Meyer R.A., Gray R.W., Meyer M.H. Abnormal vitamin D metabolism in the X-linked hypophosphatemic mouse. Endocrinology 1980, 107:1577-1581.
193. Lobaugh B., Drezner M.K. Abnormal regulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the X-linked hypophosphatemic mouse. J Clin Invest 1983, 71:400-403.
194. Roy S., Tenenhouse H.S. Transcriptional regulation and renal localization of 1,25-dihydroxyvitamin D3-24-hydroxylase gene expression: effects of the Hyp mutation and 1,25-dihydroxyvitamin D3. Endocrinology 1996, 137:2938-2946.
195. Tenenhouse H.S., Martel J. Renal adaptation to phosphate deprivation: lessons from the X-linked Hyp mouse. Pediatr Nephrol 1993, 7:312-318.
196. Carpenter T.O., Shiratori T. Renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity and mitochondrial phosphate transport in Hyp mice. Am J Physiol 1990, 259:E814-E821.
197. Tenenhouse H.S. Metabolism of 25-hydroxyvitamin D3 in renal slices from the X-linked hypophosphatemic (Hyp) mouse: abnormal response to fall in serum calcium. Cell Calcium 1984, 5:43-55.
198. Tenenhouse H.S. Abnormal renal mitochondrial 25-hydroxyvitamin D3-1-hydroxylase activity in the vitamin D and calcium deficient X-linked Hyp mouse. Endocrinology 1983, 113:816-818.
199. Nesbitt T., Drezner M.K., Lobaugh B. Abnormal parathyroid hormone stimulation of 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the hypophosphatemic mouse. Evidence for a generalized defect of vitamin D metabolism. J Clin Invest 1986, 77:181-187.
200. Nesbitt T., Lobaugh B., Drezner M.K. Calcitonin stimulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in hypophosphatemic mice. Evidence that the regulation of calcitriol production is not universally abnormal in X-linked hypophosphatemia. J Clin Invest 1987, 79:15-19.
201. Tenenhouse H.S., Scriver C.R. Effect of 1,25-dihydroxyvitamin D3 on phosphate homeostasis in the X-linked hypophosphatemic (Hyp) mouse. Endocrinology 1981, 109:658-660.
202. Perwad F., Zhang M.Y., Tenenhouse H.S., Portale A.A. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007, 293:F1577-F1583.
203. Ecarot-Charrier B., Glorieux F.H. Effects of phosphate and 1,25(OH)2D3 on in vitro bone collagen synthesis in the hypophosphatemic mouse. Calcif Tissue Int 1983, 35:383-391.
204. Yamamoto T., Ecarot B., Glorieux F.H. Abnormal response of osteoblasts from Hyp mice to 1,25-dihydroxyvitamin D3. Bone 1992, 13:209-215.
205. Tenenhouse H.S., Fast D.K., Scriver C.R., Koltay M. Intestinal transport of phosphate anion is not impaired in the Hyp (hypophosphatemic) mouse. Biochem Biophys Res Commun 1981, 100:537-543.
206. Nakagawa N., Ghishan F.K. Sodium-phosphate transport in the kidney and intestine of the hypophosphatemic mouse. Pediatr Nephrol 1993, 7:815-818.
207. Brault B.A., Meyer M.H., Meyer R.A. Malabsorption of phosphate by the intestines of young X-linked hypophosphatemic mice. Calcif Tissue Int 1988, 43:289-293.
208. Meyer M.H., Meyer R.A., Iorio R.J. A role for the intestine in the bone disease of juvenile X-linked hypophosphatemic mice: malabsorption of calcium and reduced skeletal mineralization. Endocrinology 1984, 115:1464-1470.
209. Meyer R.A., Meyer M.H., Erickson P.R., Korkor A.B. Reduced absorption of 45calcium from isolated duodenal segments in vivo in juvenile but not adult X-linked hypophosphatemic mice. Calcif Tissue Int 1986, 38:95-102.
210. Bruns M.E., Meyer R.A., Meyer M.H. Low levels of intestinal vitamin D-dependent calcium-binding protein in juvenile X-linked hypophosphatemic mice. Endocrinology 1984, 115:1459-1463.
211. Bruns M.E., Christakos S., Huang Y.C., Meyer M.H., Meyer R.A. Vitamin D-dependent calcium binding proteins in the kidney and intestine of the X-linked hypophosphatemic mouse: changes with age and responses to 1,25-dihydroxycholecalciferol. Endocrinology 1987, 121:1-6.
212. Seino Y., Sierra R.I., Ichikawa M., Avioli L.V. I Alpha, 25-dihydroxyvitamin D3 receptor in the X-linked hypophosphatemic mouse. Endocrinology 1982, 111:329-331.
213. Nakajima S., Yamaoka K., Okada S., Pike J.W., Seino Y., Haussier M.R. 1,25-Dihydroxyvitamin D3 does not up-regulate vitamin D receptor messenger ribonucleic acid levels in hypophosphatemic mice. Bone Miner 1992, 19:201-213.
214. Meyer R.A., Meyer M.H., Gray R.W., Bruns M.E. Evidence that low plasma 1,25-dihydroxyvitamin D causes intestinal malabsorption of calcium and phosphate in juvenile X-linked hypophosphatemic mice. J Bone Miner Res 1987, 2:67-82.
215. Yamamoto T., Seino Y., Yamaoka K., Yabuuchi H. Decreased nuclear uptake of 1,25-dihydroxyvitamin D3 by duodenal mucosal cells in the X-linked hypophosphatemic mouse. Endocrinology 1985, 117:2252-2254.
216. Yamamoto T., Seino Y., Tanaka H., et al. Effects of the administration of phosphate on nuclear 1,25-dihydroxyvitamin D3 uptake by duodenal mucosal cells of Hyp mice. Endocrinology 1988, 122:576-580.
217. Du L., Desbarats M., Viel J., Glorieux F.H., Cawthorn C., Ecarot B. cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics 1996, 36:22-28.
218. Strom T.M., Francis F., Lorenz B., et al. Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet 1997, 6:165-171.
219. Guo R., Quarles L.D. Cloning and sequencing of human PEX from a bone cDNA library: evidence for its developmental state-specific regulation in osteoblasts. J Bone Miner Res 1997, 12:1009-1017.
220. Wang L., Du L., Ecarot B. Evidence for Phex haploinsufficiency in murine X-linked hypophosphatemia. Mamm Genome 1999, 10:385-389.
221. Grieff M., Whyte M.P., Thakker R.V., Mazzarella R. Sequence analysis of 139 kb in Xp22.1 containing spermine synthase and the 5' region of PEX. Genomics 1997, 44:227-231.
222. Lorenz B., Francis F., Gempel K., et al. Spermine deficiency in Gy mice caused by deletion of the spermine synthase gene. Hum Mol Genet 1998, 7:541-547.
223. Meyer R.A., Henley C.M., Meyer M.H., et al. Partial deletion of both the spermine synthase gene and the Pex gene in the X-linked hypophosphatemic, gyro (Gy) mouse. Genomics 1998, 48:289-295.
224. Ruchon A.F., Tenenhouse H.S., Marcinkiewicz M., et al. Developmental expression and tissue distribution of Phex protein: effect of the Hyp mutation and relationship to bone markers. J Bone Miner Res 2000, 15:1440-1450.
225. Lipman M.L., Panda D., Bennett H.P., et al. Cloning of human PEX cDNA. Expression, subcellular localization, and endopeptidase activity. J Biol Chem 1998, 273:13729-13737.
226. Ruchon A.F., Marcinkiewicz M., Siegfried G., et al. Pex mRNA is localized in developing mouse osteoblasts and odontoblasts. J Histochem Cytochem 1998, 46:459-468.
227. Ecarot B., Desbarats M. 1,25-(OH)2D3 down-regulates expression of Phex, a marker of the mature osteoblast. Endocrinology 1999, 140:1192-1199.
228. Meyer R.A., Young C.G., Meyer M.H., Garges P.L., Price D.K. Effect of age on the expression of Pex (Phex) in the mouse. Calcif Tissue Int 2000, 66:282-287.
229. Blydt-Hansen T.D., Tenenhouse H.S., Goodyer P. PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Pediatr Nephrol 1999, 13:607-611.
230. Miyamura T., Tanaka H., Inoue M., Ichinose Y., Seino Y. The effects of bone marrow transplantation on X-linked hypophosphatemic mice. J Bone Miner Res 2000, 15:1451-1458.
231. Liu S., Guo R., Tu Q., Quarles L.D. Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem 2002, 277:3686-3697.
232. Boskey A., Frank A., Fujimoto Y., et al. The PHEX transgene corrects mineralization defects in 9-month-old hypophosphatemic mice. Calcif Tissue Int 2009, 84:126-137.
233. Sabbagh Y., Boileau G., DesGroseillers L., Tenenhouse H.S. Disease-causing missense mutations in the PHEX gene interfere with membrane targeting of the recombinant protein. Hum Mol Genet 2001, 10:1539-1546.
234. Boileau G., Tenenhouse H.S., Desgroseillers L., Crine P. Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide 107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochem J 2001, 355:707-713.
235. Liu S., Guo R., Simpson L.G., Xiao Z.S., Burnham C.E., Quarles L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003, 278:37419-37426.
236. Ichikawa S., Austin A.M., Gray A.K., Econs M. Phex mutations in a murine model of X-linked hypophosphatemia result in impaired phosphate sensing. J Bone Miner Res 2010, 25(S1). Available at, Accessed February 10, 2011. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=3e23 c74e-dd91-461b-b631-4fc47be274a9.
237. Imel E.A., DiMeglio L.A., Hui S.L., Carpenter T.O., Econs M.J. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 2010, 95:1846-1850.
238. Carpenter T.O., Insogna K.L., Zhang J.H., et al. Circulating levels of soluble klotho and FGF-23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 2010, 95:E352-E357.
239. Econs M.J., McEnery P.T., Lennon F., Speer M.C. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 1997, 100:2653-2657.
240. Liu S., Zhou J., Tang W., Jiang X., Rowe D.W., Quarles L.D. Pathogenic role of FGF-23 in Hyp mice. Am J Physiol Endocrinol Metab 2006, 29:E38-E49.
241. Meyer R.A. Elevated mRNA gene expression of fibroblast growth factor 23 (FGF-23) in the thymus of X-linked hypophosphatemic (Hyp) mice. J Bone Miner Res 2001, 16(S251). Available at: http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey ={F45961FC-93EF-4C35-86A5-B4796302EA43}&SKey={EB5BC322-4BB8-47A0-92C 9-F1C5DE967B90}&MKey=A3C75A6C-2DD6-4EB3-9C22-D35081DC2990&AKey={ D0C01D4F-E23B-45E2-ACD4-0AF8AC866B8B} Accessed February 10, 2011.
242. White K.E., Carn G., Lorenz-Depiereux B., Benet-Pages A., Strom T.M., Econs M.J. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001, 60:2079-2086.
243. Seidah N.G., Chretien M. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res 1999, 848:45-62.
244. Kurosu H., Ogawa Y., Miyoshi M., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006, 281:6120-6123.
245. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
246. Kurosu H., Kuro-O M. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 2009, 299:72-78.
247. Razzaque M.S., Sitara D., Taguchi T., St-Arnaud R., Lanske B. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D mediated process. FASEB J 2006, 20:720-722.
248. Ichikawa S., Imel E.A., Kreiter M.L., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007, 117:2684-2691.
249. Brownstein C.A., Adler F., Nelson-Williams C., et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 2008, 105:3455-3460.
250. Farrow E.G., Summers L.J., Schiavi S.C., McCormick J.A., Ellison D.H., White K.E. Altered renal FGF-23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation. J Endocrinol 2010, 207:67-75.
251. Urakawa I., Yamazaki Y., Shimada T., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF-23. Nature 2006, 444:770-774.
252. Li H., Martin A.C., David V., Quarles L.D. Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. Am J Physiol Endocrinol Metab 2010;Dec 7., [Epub ahead of print.].
253. Beck L., Karaplis A.C. Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci USA 1998, 95:5372-5377.
254. Miedlich S.U., Zhu E.D., Sabbagh Y., Demay M.B. The receptor-dependent actions of 1,25-dihydroxyvitamin D are required for normal growth plate maturation in NPt2a knockout mice. Endocrinology 2010, 151:4607-4612.
255. Bergwitz C., Roslin N.M., Tieder M., et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006, 78:179-192.
256. Sabbagh Y., O'Brien S.P., Song W., et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 2009, 20:2348-2358.
257. Corut A., Senyigit A., Ugur S.A., et al. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet 2006, 79:650-656.
258. Brown W.W., Jüppner H., Langman C.B., et al. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 2009, 94:17-20.
259. Karim Z., Gérard B., Bakouh N., et al. NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 2008, 359:1128-1135.
260. Farrow E.G., Davis S.I., Summers L.J., White K.E. Initial FGF-23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 2009, 20:955-960.